1. Potent inhibition of acetylcholinesterase by sargachromanol I from Sargassum siliquastrum and by selected natural compounds.
- Author
-
Lee JP, Kang MG, Lee JY, Oh JM, Baek SC, Leem HH, Park D, Cho ML, and Kim H
- Subjects
- Anemarrhena chemistry, Animals, Benzopyrans chemistry, Benzopyrans isolation & purification, Biological Products chemistry, Biological Products isolation & purification, Butyrylcholinesterase metabolism, Cholinesterase Inhibitors chemistry, Cholinesterase Inhibitors isolation & purification, Dose-Response Relationship, Drug, Electrophorus, Fatty Alcohols chemistry, Fatty Alcohols isolation & purification, Horses, Humans, Kinetics, Molecular Docking Simulation, Molecular Structure, Monoamine Oxidase metabolism, Myristica chemistry, Structure-Activity Relationship, Acetylcholinesterase metabolism, Benzopyrans pharmacology, Biological Products pharmacology, Cholinesterase Inhibitors pharmacology, Fatty Alcohols pharmacology, Sargassum chemistry
- Abstract
Six hundred forty natural compounds were tested for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. Of those, sargachromanol I (SCI) and G (SCG) isolated from the brown alga Sargassum siliquastrum, dihydroberberine (DB) isolated from Coptis chinensis, and macelignan (ML) isolated from Myristica fragrans, potently and effectively inhibited AChE with IC
50 values of 0.79, 1.81, 1.18, and 4.16 µM, respectively. SCI, DB, and ML reversibly inhibited AChE and showed mixed, competitive, and noncompetitive inhibition, respectively, with Ki values of 0.63, 0.77, and 4.46 µM, respectively. Broussonin A most potently inhibited BChE (IC50 = 4.16 µM), followed by ML, SCG, and SCI (9.69, 10.79, and 13.69 µM, respectively). In dual-targeting experiments, ML effectively inhibited monoamine oxidase B with the greatest potency (IC50 = 7.42 µM). Molecular docking simulation suggested the binding affinity of SCI (-8.6 kcal/mol) with AChE was greater than those of SCG (-7.9 kcal/mol) and DB (-8.2 kcal/mol). Docking simulation indicated SCI interacts with AChE at Trp81, and that SCG interacts at Ser119. No hydrogen bond was predicted for the interaction between AChE and DB. This study suggests SCI, SCG, DB, and ML be viewed as new reversible AChE inhibitors and useful lead compounds for the development for the treatment of Alzheimer's disease., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF